Načítá se...
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke
INTRODUCTION: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only FDA approved treatment for patients with acute ischemic stroke, but its use is limited by narrow therapeutic window, selective efficacy, and hemorrhagic complication. In the past two decades, extensive efforts...
Uloženo v:
| Vydáno v: | Expert Opin Drug Deliv |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5780255/ https://ncbi.nlm.nih.gov/pubmed/28944694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17425247.2018.1384464 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|